

Award Number:
W81XWH-07-1-0201

TITLE:
Determination of Optimum Vitamin D Nutrition in Young Women

PRINCIPAL INVESTIGATOR:
John Gallagher, M.D.

CONTRACTING ORGANIZATION:
Creighton University
Omaha, NE 68178

REPORT DATE:
October 2010

TYPE OF REPORT:
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-10-2010			2. REPORT TYPE Annual		3. DATES COVERED (From - To) 30 SEP 2009 - 29 SEP 2010	
4. TITLE AND SUBTITLE Determination of Optimum Vitamin D Nutrition in Young Women.					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER W81XWH-07-0201	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) John C. Gallagher, M.D. Email: jcg@creighton.edu					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Creighton University Omaha NE 68178-0410			8. PERFORMING ORGANIZATION REPORT NUMBER			
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research And Material Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release, distribution unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT The main objective of this proposal is to study the effect of increasing doses of vitamin D ₃ in a group of young women with hypovitaminosis D (serum 25OHD < 20 ng/ml) and an adequate calcium intake of 1200 -1400mg/day. This is a double blind randomized placebo controlled study .There will be 5 treatment arms, four vitamin D3 dose groups (400, 800, 1600, 2400 IU/day, placebo). Calcium citrate tablets will be given to maintain the calcium intake between 1200-1400mg/d. The study will recruit up to 120 Caucasian and 120 African American women subjects, ages 25 to 45. The primary outcomes are changes in serum 25OHD and serum PTH. Secondary outcomes are calcium absorption, physical performance tests and safety measurements of serum calcium and 24 hour urine calcium. The first year of active recruitment started on April 1 2008 and the first subject was randomized to treatment on 04/28/2008. For year one, we had 49 subjects randomized to treatment (20 African Americans, 29 Caucasians). At the end of the second year of recruitment we have randomized to treatment 168 subjects total (49 African Americans, 119 Caucasians). In the third year of the study we have undertaken numerous recruitment methods to increase African American enrollment. There are 197 subjects total randomized to treatment (78 African Americans, 119 Caucasians). Enrollment of African Americans will have to close on November 1 2010 since we are not able to recruit any more subjects and the study will finish in one year.						
15. SUBJECT TERMS - None provided.						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON	
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC	
U	U	U	UU	11	19b. TELEPHONE NUMBER (include area code)	

Table of Contents

	<u>Page</u>
Introduction	5
Body	5-6
Key Research Accomplishments	6-7
Reportable Outcomes	7
Conclusion	7
References	7
Appendices	8

Annual Report

(Oct 2009-Sept 2010)

Grant/Cooperative Agreement Number:

Proposal No. PR065013, Award No.W81XWH-07-1-0201, HRPO Log No. A-14205

Grant/Cooperative Agreement Title:

Protocol, "Determination of Optimum Vitamin D Nutrition in Young Women"

Recipient:**Principal Investigator:**

John Gallagher, M.D.
Bone Metabolism Unit
Creighton University
601 N 30th ST.Suite 6718.
Omaha NE 68131,USA
Phone: (402)280-4518, Fax: (402)280-4517
e-mail: jcg@creighton.edu

Grant Officer's Representative:

Kathleen Taggart

Abstract

The main objective of this proposal is to study the effect of increasing doses of vitamin D₃ in a group of young women with hypovitaminosis D (serum 25OHD < 20 ng/ml) and an adequate calcium intake of 1200 -1400mg/day. This is a double blind randomized placebo controlled study .There will be 5 treatment arms, four vitamin D3 dose groups (400, 800, 1600, 2400 IU/day, placebo). Calcium citrate tablets will be given to maintain the calcium intake between 1200-1400mg/d. The study will recruit up to 120 Caucasian and 120 African American women subjects, ages 25 to 45. The primary outcomes are changes in serum 25OHD and serum PTH. Secondary outcomes are calcium absorption, physical performance tests and safety measurements of serum calcium and 24 hour urine calcium. The first year of active recruitment started on April 1 2008 and the first subject was randomized to treatment on 04/28/2008. For year one, we had 49 subjects randomized to treatment (20 African Americans, 29 Caucasians). At the end of the second year of recruitment we have randomized to treatment 168 subjects total (49 African Americans, 119 Caucasians). In the third year of the study we have undertaken numerous recruitment methods to increase African American enrollment. There are 197 subjects total randomized to treatment (78 African Americans, 119 Caucasians). Enrollment of African Americans will have to close on November 1 2010 since w are not able to recruit any more subjects and the study will finish in one year.

Introduction

The diagnosis of vitamin D deficiency (serum 25OHD<12ng/ml) and vitamin D insufficiency (serum 25OHD<20ng/ml) have become more common in the last 3 years as health professionals became more aware of this issue. It has been suggested that a serum 25OHD level of 30ng/ml is optimal for bone health because serum parathyroid hormone levels are lower at this level and markers of bone resorption are decreased. It is also suggested that the RDA (Recommended Dietary Allowance) for vitamin D should use this serum 25OHD level as a goal when estimating the RDA. Because there have been no systematic dose response studies on vitamin D we postulate that the minimal dose of vitamin D that will achieve a serum 25OHD of 30 ng/ml in 97 percent of young women during the winter will exceed 1700 IU/day in Caucasian and 2000 IU/day in African American women. This is much higher than the present RDA of 400-600 IU/day which may need to be revised upwards if this hypothesis is confirmed. To measure the dose response we will use vitamin D₃ doses of 400, 800, 1600, and 2400 IU/day plus a calcium intake of 1200-1400mg/day compared with a placebo group and similar calcium intake.

Body

Funding for this study started on October 6, 2007. The first six months involved development of a protocol, construction of subject charts, submission to the local IRB and approval by DOD. There was a significant delay in obtaining final approval by HRPO.

10/6/2006	Award Notice	Pamela Fisle
10/10/2006	Development of protocol and forms	
12/13/2006	Initiate document submission	Amber Stanley
1/25/2007	Protocol submitted to DOD	Dr. Gallagher
9/8/2007	IRB approval of protocol	Dr Gallagher
10/1/2007	Funding started	
10/16/2007	PEF comment	Johanna Kidwell
11/19/2007	Reply to PEF.	Dr. Gallagher
12/20/2007	PEF further comments.	Johanna Kidwell
1/10/2008	PEF further comments.	Johanna Kidwell
1/24/2008	Creighton IRB approval of protocol & forms.	Dr Gallagher
2/18/2008	UNMC IRB approval.	Dr Gallagher
2/19/2008	Study drug arrived.	
2/26/2008	DSMB Conference completed. No issues arose.	
3/19/2008	Final approval by HRPO.	
3/19/2008	Clinical trial registered NCT00662844.	
4/1/2008	Recruitment started.	
5/23/2008	Creighton IRB approval of consents revision (personnel change).	
9/16/2008	Creighton IRB renewal approval & consent revision (personnel change).	
2/11/2009	Creighton IRB approval of protocol revision & consents (ethnic group size increase (100 to 120), Amendment 1.	
3/13/2009	HRPO revision request to protocol & consents.	

3/18/2009	Creighton IRB approval of protocol revision & consents.
3/27/2009	HRPO approval of protocol revision & consents.
9/15/2009	Creighton IRB renewal approval.
09/07/2010	Creighton IRB renewal approval.

Recruitment: Because serum 25OHD is lowest in the months January to May we have a restricted window for recruitment. As a result of the delayed approval by HRPO we were only able to recruit for 2 months in the first year- 2008.

Summarizing our activity to date we have screened a total of 1512 women on the phone. 590 qualified by phone screening and scheduled an informational screening visit came in and signed consent forms. Of the 557 that signed consent, 305 qualified on the basis of low serum 25OHD and 197 were randomized to a treatment group. A complete summary to date of our subject contact and recruitment is shown in table 1 in the appendix. This table illustrates some of the problems and difficulties associated with recruitment. Of those subjects that had a screening blood sample drawn, 55% qualify on the basis of low serum 25OHD; however, only 35% of those screened would eventually be randomized to study drug. Another issue is that 27% of those that schedule an informational screening meeting are 'no shows' and many of them are repeated 'no shows' even after rescheduling. The same can be seen of those subjects that qualify for randomization. 28% of these subjects do not get randomized to treatment ('no shows' or 'withdrew'). In the 'no show' category are those subjects who we have not been able to contact to date and have not returned phone messages. If any 'no show' has been contacted they may have come back or given us a reason why they are declining participation ('withdrew') and then have been moved out of the 'no show' category. We have employed visit reminder post cards and phone calls/messages as methods to help alleviate the 'no show' issue.

African American subjects have been difficult to recruit and during year two we took steps to aid in recruitment. Recruitment flyer mailings, targeted mailings, multiple radio advertisements, recruiting booths at health events and recruitment informational events at companies have all been employed. While continuing the above in year three we also added walking campaigns targeting small businesses in several areas of town, leaving flyers with business owners that allow community event postings in their stores; as well as meeting with church and community/business groups. Our goal has been to try and get a one-on-one informational session with a potential subject in order to make them feel comfortable with the project and staff.

The study has been completed on all Caucasian women and this past year has been devoted to follow-up of randomized subjects and recruitment of new African American subjects.

Results: The following is an excerpt from the July 2010 DSMB report showing baseline characteristics stratified by race and longitudinal plots of the serum and urine calcium results for randomized subjects.

Baseline Characteristics

Baseline characteristics are compared by treatment assignment stratified by race.

Baseline Characteristics for African Americans (n=70)

	Dose V (n=16)	Dose W (n=13)	Dose X (n=14)	Dose Y (n=13)	Dose Z (n=14)
Age: mean (SD)	35.0 (5.3)	35.0 (5.9)	34.7 (6.5)	38.0 (5.8)	36.4 (6.7)
Height (cm): mean (SD)	162 (6.2)	164 (3.9)	164 (7.0)	165 (5.9)	164 (4.3)
Weight (kg): mean (SD)	82.3 (16.2)	96.4 (21.6)	78.6 (19.7)	88.0 (20.5)	86.0 (20.6)
BMI: mean (SD)	31.4 (5.8)	35.5 (7.1)	28.8 (5.2)	32.3 (6.3)	31.9 (6.8)
Smoking status: N (%)					
Current smoker	2 (12.5%)	3 (23%)	2 (14%)	2 (15%)	2 (14%)
Former smoker	2 (12.5%)	3 (23%)	1 (7%)	1 (8%)	2 (14%)
Non-smoker	12 (75%)	7 (54%)	11 (79%)	10 (77%)	10 (71%)
Alcohol use: N (%)					
No	4 (25%)	5 (38%)	5 (36%)	4 (31%)	4 (29%)
Yes	12 (75%)	8 (62%)	9 (64%)	9 (69%)	10 (71%)
Total Body BMD: mean (SD)	1.19 (0.08)	1.27 (0.14)	1.20 (0.10)	1.27 (0.10)	1.25 (0.11)
Serum 25OHD: mean (SD)	11.4 (4.0)	13.2 (4.8)	10.9 (3.2)	10.7 (3.4)	9.5 (4.3)
Serum Ca (mg/dl): mean (SD)	9.25 (0.33)	9.15 (0.29)	9.21 (0.32)	8.92 (0.24)	9.11 (0.34)
24 hr Urine Ca (mg): mean (SD)	143 (78)	120 (53)	122 (71)	101 (82)	99 (61)
<i>Food Diary Results:</i>					
Calcium intake/day (mg) : mean (SD)	532 (193)	550 (152)	498 (147)	450.3 (154)	521 (184)
Vitamin D intake/day (IU) : mean (SD)	70 (63)	100 (42)	74 (46)	111 (114)	132 (104)
Fiber intake/day (g) : mean (SD)	12 (3.3)	14 (6)	11 (4)	11 (3.1)	14 (5.9)
Caffeine intake/day (mg): mean (SD)	47 (61)	91 (143)	37 (53)	61 (67)	41 (53)

Baseline Characteristics for Caucasians (n=119)


	Dose V (n=24)	Dose W (n=25)	Dose X (n=21)	Dose Y (n=23)	Dose Z (n=26)
Age: mean (SD)	39.4 (5.7)	38.8 (4.6)	38.4 (6.5)	36.4 (6.6)	38.2 (4.5)
Weight (kg): mean (SD)	164 (5.9)	167 (7.3)	167 (7.1)	166 (6.3)	165 (5.1)
Height (cm): mean (SD)	82.9 (15.9)	77.8 (16.4)	77.9 (20.0)	81.9 (17.7)	73.9 (14.5)
BMI: mean (SD)	31.0 (6.2)	27.9 (5.1)	28.1 (7.2)	29.7 (6.6)	27.2 (5.1)
Smoking status: N (%)					
Current smoker	5 (21%)	4 (16%)	6 (29%)	3 (13%)	7 (27%)
Former smoker	5 (21%)	4 (16%)	6 (29%)	4 (17%)	4 (15%)
Non-smoker	14 (58%)	17 (68%)	9 (43%)	16 (70%)	15 (58%)
Alcohol use: N (%)					
No	5 (21%)	8 (32%)	6 (29%)	6 (26%)	4 (15%)
Yes	19 (79%)	17 (68%)	15 (71%)	17 (74%)	22 (85%)
Total Body BMD: mean (SD)	1.15 (0.09)	1.15 (0.09)	1.16 (0.07)	1.2 (0.09)	1.16 (0.08)
Serum 25OHD level: mean (SD)	14.9 (4.1)	14.5 (4.9)	14.4 (4.5)	13.7 (4.2)	15.0 (4.5)

Serum Ca (mg/dl): mean (SD)	9.21 (0.21)	9.13 (0.34)	9.23 (0.30)	9.17 (0.33)	9.19 (0.25)
24 hr Urine Ca (mg): mean (SD)	127 (73)	150 (74)	157 (74)	148 (81)	179 (68)
<i>Food Diary Results:</i>					
Calcium intake/day (mg) : mean (SD)	659 (267)	781 (266)	735 (258)	764 (283)	782 (290)
Vitamin D intake/day (IU) : mean (SD)	105 (79)	91 (42)	112 (74)	102 (61)	111 (76)
Fiber intake/day (g) : mean (SD)	15 (5.9)	14 (4.4)	16 (6.0)	15 (4.1)	15 (5.1)
Caffeine intake/day (mg): mean (SD)	142 (124)	166 (141)	125 (107)	142 (182)	184 (167)

The following figures show boxplots of the serum and urine calcium levels at the 5 visits, combining dose levels and races. As per protocol several of the measurements had to be repeated. If multiple measurements were done, then the first level was used for the following analysis (usually the highest). The boxplot shows the distribution of the data. The line in the middle of the box is the median (50th percentile), the plus symbol is the mean, the lower edge of the box is the 1st quartile (25th percentile), the upper edge of the box is the 3rd quartile (75th percentile), and the lines extending from the box (called whiskers) show the minimum and maximum of the data.


From the boxplot, figure 1 we can see the distribution of serum calcium levels. None had serum calcium levels greater than 10.6 mg/dl.

Figure 1. Serum calcium data.



From the boxplot, figure 2, we can see the distribution of the 24 hour urine calcium levels. 5 (1.0%) subjects had elevated urine calcium at baseline, 1 (2.2%) subject had elevated at the 3 month visit, 0 (0%) subjects were elevated at the 6 month visit, 1 (5.2%) subject was elevated at the 9 month visit, and 0 (0%) subjects had elevated urine calcium at the 12 month visit.

Figure 2. Urine calcium data



Progress of Randomized Subjects: As of October 2010, 112 subjects have completed study (23 African Americans and 89 Caucasians) and 62 have dropped from study after randomization to treatment. Of those dropped, 'lost to follow up' (40) is the biggest category and contains those subjects that did not have a clearly defined reason for withdrawal. 23 African American subjects are currently still undergoing study visits.

Reportable Outcomes

There are no primary outcomes to report yet as subjects are still undergoing visits as per protocol. The outcomes to be studied are given below.

Primary outcomes of the study are serum 25OHD and PTH levels at the end of the first year of treatment.

Secondary outcome measures are to study the safety of these doses on serum calcium and urine calcium.

Safety: Serum calcium and 24 hour urine calcium are measured every 3 months. Two subjects have developed hypercalciuria (> 400mg/24h). Both subjects followed the hypercalciuria management protocol and a re-test requested. On re-test, the 24 hour urine calcium of one subject dropped well below 400mg. The other subject refused multiple requests for re-test and was withdrawn from study. There have been no serious adverse events reported.


Conclusion

Caucasian recruitment goals have been met and this group has completed study. African American recruitment has been disappointing, considerable extra effort has taken place to develop and implement methods beyond those typically used for recruitment.

References

None.

Appendix - Table 1



Drops: 32 AA: 1 AE, 1 Pregnant, 1 Health Concern, 27 Lost, 1 Scheduling, 1 No reason provided
 30 C: 2 AE, 3 Health Concern, 13 Lost, 1 Noncompliant, 5 Personal, 4 Scheduling, 2 No reason provided

Completed Study: 112 total: 23 AA, 89 C
 In study: 23 total: 23 AA, 0 C

AA = African American
 C = Caucasian
 O = All other ethnic groups (excluded from study)